ImmuPharma awarded $1.1M to advance Ph I cancer drug
UK-headquartered drug developer ImmuPharma has been awarded 900,000 euros ($1.2 million) as one of the two grants it has been anticipating from French government organizations. The grants are to be used for the development of ImmuPharma's cancer drug candidate IPP-204106.
Robert Zimmer, chief scientific officer of the firm, said: "we are both delighted and honored to have been chosen for the grant by this prestigious French government organization. Together with the company's internal resources, this grant will fund the development of our exciting cancer compound to the completion of Phase I trials, which we expect to start during 2009."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze